Endometriosis
Conditions
Interventions
Sponsors
Kikuyama Ryoko
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: - Japanese premenopausal female patients who are aged 18 years or older - Patients who have been diagnosed with endometriosis - Patients who had consecutive days of bleeding - Patients who, along with their partners, are capable of using appropriate contraception during the study period
Exclusion criteria
Exclusion criteria: - Patients who have had a hysterectomy or bilateral oophorectomy - Patients with ovarian chocolate cysts measuring >= 10 cm and are aged 40 years or older at the time of examination - Patients with a current history of thyroid dysfunction with irregular menstruation, or with a potential for irregular menstruation due to thyroid dysfunction - Patients with undiagnosed abnormal genital bleeding - Patients with marked metrorrhagia or anovulatory bleeding - Patients with uterine fibroids requiring treatment - Patients with lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis - Patients with current or previous osteoporosis, osteopenia, or other metabolic bone diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in maximum VAS score for endometriotic pelvic pain from 20 to 24 weeks after administration of study drug | — |
Contacts
Public ContactRyoko Kikuyama
ASKA Pharmaceutical Co., Ltd.
Outcome results
None listed